Clinical Trials Logo
  1. Home
  2. Progression-free Survival
  3. NCT03359018

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma — APFAO  

Toxicity Clinical Trial

Official title:
Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial

Clinical Trial Summary

After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades. We have already finished a prospective trial about apatinib for advanced osteosarcoma(NCT02711007) and find it has a objective response rate of aproximately 45% with median progression-free survival around 5 months. Thus, the investigators explored apatinib activity together with anti-PD1 therapy in order to induce durable response in patients with relapsed and unresectable osteosarcoma after the failure of first-line or second-line chemotherapy.

Apatinib is a small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor, similar to pazopanib, but with a binding affinity 10 times to VEGFR-2 comparing with pazopanib or sorafenib.

SHR-1210 is a humanized anti-PD-1 monoclonal antibody.

Clinical Trial Description

Patients more than 11 years with body surface area more than 1.2m2, progressing after standard treatment, will be eligible to receive 250 or 500 mg of apatinib once daily together with SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until progression or unacceptable toxicity. The primary end point was progression-free survival (PFS) at 4 months and overall survival(OS). Secondary objectives were clinical benefit rate (CBR), defined as no progression at 6 months and safety. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03359018
Study type Interventional
Source Peking University People's Hospital
Contact
Status Completed
Phase Phase 2
Start date January 1, 2018
Completion date January 30, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02273713 - The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) Phase 1/Phase 2
Terminated NCT00531076 - Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer Phase 1
Active, not recruiting NCT02397434 - Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer N/A
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Active, not recruiting NCT02649491 - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy N/A
Active, not recruiting NCT03975452 - Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer N/A
Terminated NCT00618917 - MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Not yet recruiting NCT02760823 - Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning Phase 2
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT00890448 - Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate N/A
Terminated NCT01760356 - Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
Recruiting NCT06044623 - Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients Phase 3
Completed NCT01091766 - Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine Phase 4
Completed NCT05277480 - Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Phase 2
Recruiting NCT03978949 - Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP) Phase 3
Completed NCT03491371 - Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use N/A
Completed NCT02143219 - Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Phase 2
Completed NCT02054741 - Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer N/A
Not yet recruiting NCT06087718 - Feasibility of the Maastro Applicator in Rectal Cancer N/A
Terminated NCT02512809 - Isoflurane-induced Neuroinflammation in Children With Hydrocephalus Phase 3